The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tick vector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme disease was recently removed from the market by its manufacturer further highlighting the need for new approaches to controlling the disease. In this project, we propose the development of an orally-available vaccine targeted towards the mouse and tick reservoirs of the disease. This proposal combines the expertise of Foodsource Lure Corp, a manufacturer of animal baits that is currently involved in the development of wildlife-targeted vaccines for rabies and the laboratory of Dr. Linden Hu at Tufts University. Dr. Hu's laboratory has developed an oral vaccine for mice using a vaccinia virus vector expressing the B. burgdorferi protein outer surface protein A (OspA). The laboratory has shown that this vaccine (VV-OspA) produces an immune response in mice directed against OspA that is able to protect uninfected mice from acquiring infection during feeding of infected ticks. In addition, administration of the vaccine to mice already infected with B. burgdorferi prevents transmission of the organism to uninfected ticks, thus providing two mechanisms by which the vaccine may decrease transmission of the organism in wild reservoirs. In this phase I STTR proposal, we will take the initial steps towards moving the VV-OspA vaccine out of the laboratory and into field trials. In this proposal, we will test different proprietary formulations and manufacturing processes to develop a product for delivery of VV-OspA to mice in the field. The product will be tested for the stability of VV-OspA through the manufacturing process, the palatability of the product to wild mice, the uptake penetration level of baits placed in the wild and the ability of the final product to replicate protection previously determined with gavage of the vaccine when fed to caged mice. At the completion of phase I, we will have a finished VV-OspA vaccine bait suitable for environmental testing in phase II. In addition, we will have gathered important information about distribution strategies for bait placement that will be important in the planning of a phase II field trial. We believe that reservoir targeted strategies for controlling vector transmitted diseases will be an important addition to the armamentarium for prevention of human disease. ? ?

Public Health Relevance

Lyme disease is a significant public health problem in the U.S. One potential approach to the control of Lyme disease is to reduce carriage of the organisms in their wild-life reservoirs. In this proposal, we outline a strategy to develop a vaccine, targeted at mice and ticks that serve as the reservoir for the bacteria that causes Lyme disease. By decreasing carriage of the organism in the wildlife reservoirs and vectors, we hope to reduce the incidence of human disease. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41AI078631-01
Application #
7481777
Study Section
Special Emphasis Panel (ZRG1-IMM-K (12))
Program Officer
Breen, Joseph J
Project Start
2008-08-01
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
1
Fiscal Year
2008
Total Cost
$299,923
Indirect Cost
Name
Foodsource Lure Corporation
Department
Type
DUNS #
144755324
City
Birmingham
State
AL
Country
United States
Zip Code
35222
Lemieux, Jacob E; Tran, Alice D; Freimark, Lisa et al. (2016) A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse. Nat Microbiol 1:16079
Kern, Aurelie; Zhou, Chensheng W; Jia, Feng et al. (2016) Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release. Vaccine 34:4507-4513
Telford 3rd, Sam R; Goethert, Heidi K; Molloy, Philip J et al. (2015) Borrelia miyamotoi Disease: Neither Lyme Disease Nor Relapsing Fever. Clin Lab Med 35:867-82
Molloy, Philip J; Telford 3rd, Sam R; Chowdri, Hanumara Ram et al. (2015) Borrelia miyamotoi Disease in the Northeastern United States: A Case Series. Ann Intern Med 163:91-8
Gugliotta, Joseph L; Goethert, Heidi K; Berardi, Victor P et al. (2013) Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med 368:240-5
Chowdri, Hanumara Ram; Gugliotta, Joseph L; Berardi, Victor P et al. (2013) Borrelia miyamotoi infection presenting as human granulocytic anaplasmosis: a case report. Ann Intern Med 159:21-7
Bensaci, Mekki; Bhattacharya, Debaditya; Clark, Roger et al. (2012) Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi. Vaccine 30:6040-6
Radolf, Justin D; Caimano, Melissa J; Stevenson, Brian et al. (2012) Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol 10:87-99
Bhattacharya, Debaditya; Bensaci, Mekki; Luker, Kathryn E et al. (2011) Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease. Vaccine 29:7818-25
Telford 3rd, Sam R; Cunningham, Jenny A; Waltari, Eric et al. (2011) Nest box-deployed bait for delivering oral vaccines to white-footed mice. Ticks Tick Borne Dis 2:151-5

Showing the most recent 10 out of 11 publications